"FDA grants IND clearance for Innate Pharma’s solid tumour trial" was originally created and published by Clinical Trials ...

Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry, a Cambrex company, has successfully developed a new liquid-phase ...

Incendia Therapeutics has enrolled the first subject in a Phase Ic clinical trial of PRTH-101, a novel DDR1 inhibitor aimed ...

The FDA granted fast track designation to EO-3021 for the treatment of advanced or metastatic gastric and gastroesophageal ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Immuneering Corporation (NASDAQ:IMRX) released initial response data from the first five patients treated with IMM-1-104 in ...

Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the Company will ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ...

Additional Phase 2 studies in solid tumors are planned to begin in 2025.” CBX-12 is designed to deliver higher concentrations of exatecan, a topoisomerase 1 (TOP1) inhibitor, directly to tumor ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.